← All trials
NCT05600322
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2022
- Primary completion
- Aug 31, 2023
- Completion date
- Aug 31, 2023
- First posted
- Oct 31, 2022
- Last posted
- Oct 31, 2022
- Enrollment
- 380
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- PhotocureLead sponsor
- Jiangsu Asieris Pharmaceutical Technology Co., Ltd.Collaborator
- Chinese Academy of Medical SciencesOverall official - principal investigator
- Chinese Academy of Medical SciencesOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.